FDA Approves Tzield for Recently Diagnosed Type 1 Diabetes in Youth
The approval expands access to a disease-modifying therapy for children and teens diagnosed with stage 3 type 1 diabetes. Tzield is now available to preserve remaining insulin-producing cells in newly diagnosed patients.
Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.
Key takeaways
- Tzield is now approved for ages 8-17 diagnosed with stage 3 type 1 diabetes within eight weeks of diagnosis
- This is the first disease-modifying therapy approved for stage 3 T1D, when the pancreas can no longer produce enough insulin on its own
- The PROTECT study showed Tzield preserved beta cell function and slowed disease progression in stage 3 patients
- Tzield was previously approved only for stage 2 T1D in 2022 and remains the only disease-modifying therapy available for type 1 diabetes
What the Approval Means
The U.S. Food and Drug Administration has approved Tzield for children and teens ages 8-17 with stage 3 type 1 diabetes. The approval applies to patients diagnosed within eight weeks, marking the first time a disease-modifying therapy is available at the moment of T1D diagnosis.
Stage 3 is when the body can no longer produce enough insulin to manage blood sugar levels, requiring insulin therapy. For most people, type 1 diabetes is diagnosed at this stage.
How Tzield Works
Tzield works by preserving beta cells—the insulin-producing cells in the pancreas that are under attack in type 1 diabetes. By slowing the loss of these cells, the therapy can delay further disease progression and help maintain some natural insulin production.
The PROTECT study provided evidence that Tzield preserved beta cell function in people with stage 3 T1D.
A Shift in Type 1 Diabetes Care
Until now, type 1 diabetes treatment has focused on managing symptoms—primarily through insulin therapy and blood sugar management. With this approval, newly diagnosed youth now have the option to treat the underlying disease process itself by preserving remaining insulin-producing capacity.
Tzield was first approved in 2022 for stage 2 T1D (before insulin is required) and remains the only disease-modifying therapy available for type 1 diabetes.
Evidence label
Origin: finance.yahoo.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
From Type1Cure
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Research summaryCure & AdvancementsCell Replacement Therapy: A New Frontier in Type 1 Diabetes ResearchVideo report, corroborated with 5 indexed studies
- Research summaryCure & AdvancementsWhy Beta Cells Die in Type 1 Diabetes While Alpha Cells SurviveNews report, corroborated with 2 indexed studies
- Research summaryCure & AdvancementsEarly Trial Shows Some People with Type 1 Diabetes Can Reduce or Stop Insulin—Here's What We KnowNews report, corroborated with 3 indexed studies
- Research summaryCure & AdvancementsBeta Cell Therapy: Moving From Lab Promise to Real-World TreatmentVideo report, corroborated with 2 indexed studies
- Research summaryCure & AdvancementsUnderstanding the Eleodon Trial: What Early Results ShowVideo report — unverified, pending corroboration
- Research summaryCure & AdvancementsIslet Cell Therapies Advance: What You Need to KnowNews report, corroborated with 3 indexed studies